Merck & Co Inc (MRK)

MRK on New York Consolidated

57.94USD
31 Oct 2014
Price Change (% chg)

$0.63 (+1.10%)
Prev Close
$57.31
Open
$57.95
Day's High
$58.13
Day's Low
$57.66
Volume
14,066,053
Avg. Vol
10,092,698
52-wk High
$61.33
52-wk Low
$44.62

MRK

Chart for MRK

About

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceut... (more)

Overall

Beta: 0.41
Market Cap (Mil.): $165,318.30
Shares Outstanding (Mil.): 2,884.63
Dividend: 0.44
Yield (%): 3.07

Financials

  MRK Industry Sector
P/E (TTM): 31.41 32.70 33.67
EPS (TTM): 1.82 -- --
ROI: -- 18.12 17.39
ROE: -- 18.79 18.21
Search Stocks

UPDATE 1-Bayer Q3 adj profit gains slightly on strong crop chemicals

* Shares gain 3.5 percent (Adds details on drug sales, analyst comment, shares)

30 Oct 2014

UPDATE 2-Novartis results top forecasts as new products gain momentum

* Shares up 2.2 percent (Adds details, CEO quote, shares)

28 Oct 2014

Wall St. flat after last week's big gain; energy weighs

NEW YORK - U.S. stocks ended near flat on Monday, pausing after the S&P 500's biggest weekly gain since January 2013, while energy shares fell with another decline in oil prices.

27 Oct 2014

Weak Merck sales overshadow third-quarter cost cuts

- Cost cuts enabled Merck & Co to beat third-quarter earnings forecasts but disappointing sales of its Gardasil cervical cancer vaccine and other big products sent its shares about 2 percent lower. | Video

27 Oct 2014

UPDATE 3-Weak Merck sales overshadow Q3 cost cuts

Oct 27 - Cost cuts enabled Merck & Co to beat third-quarter earnings forecasts but disappointing sales of its Gardasil cervical cancer vaccine and other big products sent its shares about 2 percent lower.

27 Oct 2014

Merck beats Q3 forecast, cost cuts offset Gardasil decline

Oct 27 - Merck & Co reported lower than expected third quarter revenue, hurt by sharply lower sales of its Gardasil vaccine against cervical cancer, but cost cuts enabled the company to beat earnings forecasts.

27 Oct 2014

Ex-Bank of New York Mellon employee pleads guilty to insider trading

NEW YORK - A former Bank of New York Mellon Corp employee on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc employee about potential pharmaceutical mergers.

24 Oct 2014

UPDATE 1-Ex-Bank of New York Mellon employee pleads guilty to insider trading

NEW YORK, Oct 24 - A former Bank of New York Mellon Corp employee on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc employee about potential pharmaceutical mergers.

24 Oct 2014

Ex-Bank of New York Mellon trader pleads guilty to insider trading

NEW YORK, Oct 24 - A former Bank of New York Mellon Corp trader on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc employee about potential pharmaceutical mergers.

24 Oct 2014

Roche, Merck extend immunotherapy fight to breast cancer

LONDON - Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumors to another cancer type.

17 Oct 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks